The present study shows that imatinib treatment causes an early downregulation of the expression of glycolytic enzymes and an upregulation of mitochondrial complex subunits in BCR-ABL driven CML cells leading to a reduction of glucose consumption and an increase of intracellular ATP production. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.